Assessing How Consumers Interpret and Act on Results From At-Home COVID-19 Self-test Kits A Randomized Clinical Trial

被引:21
|
作者
Woloshin, Steven [1 ,2 ]
Dewitt, Barry [3 ,4 ]
Krishnamurti, Tamar [5 ]
Fischhoff, Baruch [3 ]
机构
[1] Dartmouth Inst Hlth Policy & Clin Practice, Ctr Med Media, Lebanon, NH 03756 USA
[2] Lisa Schwartz Fdn Truth Med, Norwich, VT USA
[3] Carnegie Mellon Univ, Dept Engn & Publ Policy, Pittsburgh, PA 15213 USA
[4] Lund Univ, Dept Clin Sci, Med Eth, Lund, Scania, Sweden
[5] Univ Pittsburgh, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA
基金
美国医疗保健研究与质量局;
关键词
D O I
10.1001/jamainternmed.2021.8075
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE The US Food and Drug Administration (FDA) authorized SARS-CoV-2 rapid at-home self-test kits for individuals with and without symptoms. How appropriately users interpret and act on the results of at-home COVID-19 self-tests is unknown. OBJECTIVE To assess how users of at-home COVID-19 self-test kits interpret and act on results when given instructions authorized by the FDA, instructions based on decision science principles, or no instructions. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial was conducted of 360 adults in the US who were recruited in April 2021 to complete an online survey on their interpretation of at-home COVID-19 self-test results. Participants were given 1 of 3 instruction types and were presented with 1 of 4 risk scenarios. Participants were paid $5 and had a median survey completion time of 8.7 minutes. Data analyses were performed from June to July 2021. INTERVENTION Participants were randomized to receiving either the FDA-authorized instructions (authorized), the intervention instructions (intervention), or no instructions (control), and to 1 of 4 scenarios: 3 with a high pretest probability of infection (COVID-19 symptoms and/or a close contact with COVID-19) and 1 with low pretest probability (no symptoms and no contact). The intervention instructions were designed using decision science principles. MAIN OUTCOMES AND MEASURES Proportion of participants in the high pretest probability scenarios choosing to quarantine per federal recommendations and perceived probabilities of infection given a negative or positive COVID-19 test result. A Bonferroni correction accounted for multiple comparisons (3 instruction types x 4 scenarios; alpha = 0.004). RESULTS After excluding 22 individuals who completed the survey too quickly, the responses of 338 participants (median [IQR] age, 38 [31 to 48] years; 154 (46%) women; 215 (64%) with a college degree or higher) were included in the study analysis. Given a positive test result, 95%(322 of 338; 95% CI, 0.92 to 0.97) of the total participants appropriately chose to quarantine regardless of which instructions they had received. Given a negative test result, participants in the high pretest probability scenarios were more likely to fail to quarantine appropriately with the authorized instructions (33%) than with the intervention (14%; 95% CI for the 19% difference, 6% to 31%; P =.004) or control (24%; 95% CI for the 9% difference, -4% to 23%; P =.02). In the low pretest probability scenario, the proportion choosing unnecessary quarantine was higher with the authorized instructions (31%) than with the intervention (22%; 95% CI for the 9% difference, -14% to 31%) or control (10%; 95% CI for the 21% difference, 0.5% to 41%)-neither comparison was statistically significant (P =.05 and P =.20 respectively). CONCLUSIONS AND RELEVANCE The findings of this randomized clinical trial indicate that at-home COVID-19 self-test kit users relying on the authorized instructions may not follow the Centers for Disease Control and Prevention's quarantine recommendations, producing unintended risks and unnecessary disruptions. Redesigned instructions that follow decision science principles may improve compliance.
引用
收藏
页码:332 / 341
页数:10
相关论文
共 50 条
  • [31] "How" Versus "Why" Messaging to Increase Uptake of Booster Vaccination Against COVID-19: Results of a Pragmatic Randomized Trial
    Haff, Nancy
    Choudhry, Niteesh K.
    Bhatkhande, Gauri
    Keller, Punam A.
    Robertson, Ted
    Oran, Rebecca
    Horn, Daniel
    Crum, Katherine L.
    Oduol, Theresa
    Hanken, Kaitlin
    Lauffenburger, Julie C.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2024, 39 (04) : 611 - 618
  • [32] “How” Versus “Why” Messaging to Increase Uptake of Booster Vaccination Against COVID-19: Results of a Pragmatic Randomized Trial
    Nancy Haff
    Niteesh K. Choudhry
    Gauri Bhatkhande
    Punam A. Keller
    Ted Robertson
    Rebecca Oran
    Daniel Horn
    Katherine L. Crum
    Theresa Oduol
    Kaitlin Hanken
    Julie C. Lauffenburger
    Journal of General Internal Medicine, 2024, 39 : 611 - 618
  • [33] A MULTIGROUP PRAGMATIC RANDOMIZED CONTROLLED TRIAL EXAMINING EFFECTS OF APP-BASED AT-HOME EXERCISE ON PSYCHOLOGICAL FUNCTIONING AND PHYSICAL HEALTH: SECONDARY ANALYSES FROM THE COVID-19 PANDEMIC AND EXERCISE (COPE) TRIAL
    Hicks, Hana
    Hives, Benjamin
    Webster, Joshua
    Liu, Yan
    Beauchamp, Mark R.
    Puterman, Eli M.
    INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2023, 30 : S138 - S138
  • [34] Awake Prone Positioning in Acute Hypoxemic Respiratory Failure from COVID-19: A Randomized Clinical Trial
    Alhazzani, W.
    Parhar, K. K. S.
    Weatherald, J.
    Al Duhailib, Z.
    Alshahrani, M.
    Al-Fares, A.
    Buabbas, S.
    Cherian, S., V
    Munshi, L.
    Fan, E.
    Al-Hameed, F.
    Chalabi, J.
    Rahmatullah, A. A.
    Duan, E.
    Tsang, J. L.
    Lewis, K.
    Lauzier, F.
    Centofanti, J.
    Rochwerg, B.
    Culgin, S.
    Nelson, K.
    Abdukahil, S. A.
    Fiest, K. M.
    Stelfox, H. T.
    Tlayjeh, H.
    Meade, M. O.
    Perri, D.
    Solverson, K.
    Niven, D. J.
    Lim, R.
    Moller, M. H.
    Belley-Cote, E.
    Thabane, L.
    Tamim, H.
    Cook, D. J.
    Arabi, Y. M.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [35] Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of the drug riamilovir for the prevention of COVID-19
    Sabitov, Alebai U.
    Lioznov, Dmitry A.
    Zhdanov, Konstantin V.
    Tihonova, Elena P.
    Esaulenko, Elena V.
    Sorokin, Pavel V.
    TERAPEVTICHESKII ARKHIV, 2024, 96 (03) : 280 - 285
  • [36] Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial
    dos Santos, Marcelo Rodrigues
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (01)
  • [37] RETRACTION: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
    Gautret, Philippe
    Lagier, Jean-Christophe
    Parola, Philippe
    Hoang, Van Thuan
    Meddeb, Line
    Mailhe, Morgane
    Doudier, Barbara
    Courjon, Johan
    Giordanengo, Valerie
    Vieira, Vera Esteves
    Dupont, Herve Tissot
    Honore, Stephane
    Colson, Philippe
    Chabriere, Eric
    La Scola, Bernard
    Rolain, Jean-Marc
    Brouqui, Philippe
    Raoult, Didier
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2025, 65 (01)
  • [38] Negative results in nucleic acid test of COVID-19 patients: assessment from the perspective of clinical laboratories
    Guo, Wenjia
    Zhou, Qi
    Xu, Jiancheng
    ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (06) : 4246 - 4251
  • [39] Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: Results from the DARE-19 Randomized Controlled Trial
    Heerspink, Hiddo J. L.
    Furtado, Remo
    Berwanger, Otavio
    Koch, Gary G.
    Martinez, Felipe
    Mukhtar, Omar
    Verma, Subodh
    Gasparyan, Samvel B.
    Tang, Fengming N.
    Windsor, Sheryl L.
    Buenconsejo, Joan
    Esterline, Russell L.
    Oscarsson, Jan
    Ambery, Philip D.
    Langkilde, Anna Maria
    Kosiborod, Mikhail
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : B5 - B6
  • [40] Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"
    Wambier, Carlos Gustavo
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (01)